| 2018-01-04 07:15:10|
SMMT, SRPT 07:15 01/04 01/04/18
Summit Therapeutics initiated with a Buy at SunTrust
SunTrust analyst Edward Nash initiated Summit Therapeutics (SMMT) with a Buy rating and a price target of $24. Nash says the company's ezutromid drug has the potential to address all 50K cases of Duchenne muscular dystrophy in the developed world, expecting the key interim data announced this quarter to be strong. The analyst notes that DMD remains a "high profile orphan disease", and only Sarepta's (SRPT) Exondys 51 treatment address about 13% of its patients.